The deliberate "stepwise" structural distortion of the [MnIII6O2(sao)6(O2CR)2L4] (S = 4, Ueff = 28 K) family of SMMs (where sao2- is the dianion of salicylaldoxime or 2-hydroxybenzaldeyhyde oxime and L = MeOH, EtOH) via the use of derivatized oxime ligands and bulky carboxylates leads to a family of single-molecule magnets with larger spin ground states and enhanced blocking temperatures. Replacing sao2- and HCO2- in the molecule [MnIII6O2(sao)6(O2CH)2(MeOH)4] (1), with Et-sao2- (Et-saoH2 = 2-hydroxypropiophenone oxime) and Me3CCO2- (pivalate), produces the complex [MnIII6O2(Et-sao)6(O2CCMe3)2(EtOH)5] (2) that displays an S = 7 ground state with Ueff = 30 K. Replacing Me3CCO2- with PhCO2- produces the complex [MnIII6O2(Et-sao)6(O2CPh)2(EtOH)4(H2O)2] (3) that displays an S = 12 ground state with Ueff = 53 K. The ligand substitution invokes a subtle structural distortion to the core of the molecule evidenced by an increased "twisting" of the oxime moiety (Mn-N-O-Mn) and a change in carboxylate ligation, which, in turn, invokes a dramatic change in the observed magnetic properties by switching weak antiferromagnetic exchange to weak ferromagnetic exchange.
No takes yet. Share an insight, caveat, or question.
Milios et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: